drugset / Trial / NCT00585546
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Phase 1
Terminated
18 enrolled
Francis D. Pagani
Georgetown University · collabMontefiore Medical Center · collabNorthwestern University · collabOhio State University · collabTexas Heart Institute · collabThoratec Corporation · collabUniversity of Minnesota · collabUniversity of Pennsylvania · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover sufficient heart function to allow the pump to be explanted. The study aims to avoid the need for transplantation in these patients by using standard heart failure medications to reduce the size of the left ventricle and then using the investigational drug, clenbuterol, to further improve left ventricular function.
Timeline
- Start
- 2007-07
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clenbuterol | Small molecule | 700 ug | Oral |